Neurizon Therapeutics
- Short interest
- 0.01%
- −0.02 pp 30d
- as of 27 Dec 2024
- Reported shorts
- 43.4K
- Shares on issue
- 491.906M
Neurizon Therapeutics (NUZ) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $0M (source: ASX (Markit))vs $0M (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$10.7MM (source: ASX (Markit))vs −$16.6M (FY25)
- ASX (Markit), as at 14 Oct 2026
- EPS (diluted)
- −$0.018vs −$0.033 (FY25)
- Yahoo Finance, as at 14 Oct 2026
- Rev YoY
- n/aFY
- EPS YoY
- n/aFY
- ASX (Markit)
Summary of Appendix 4E and 2026 Annual Report, 25 Aug 2026
Neurizon Therapeutics reported a net loss of $10.7 million for FY2026, a 35.4% improvement from the prior year's $16.6 million loss, driven by a 844.2% increase in other income to $17.8 million. No dividend was declared. The company is focused on advancing its lead therapy NUZ-001 in the Phase 2/3 HEALEY ALS Platform Trial, with topline results expected in late Q2 CY2027.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 14 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- n/a
- FCF margin
- n/a
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- −37.6×
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance, ASX (Markit) and Derived: trailing 12 months at year end, as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $0M (source: ASX (Markit)) | $0M (source: ASX (Markit)) | $0M (source: ASX (Markit)) | $2.8M |
| Gross profit | n/a | n/a | n/a | $2.0M |
| Operating income | −$27.8MT (source: Derived: trailing 12 months at year end) | −$18.5M | −$6.7M | −$3.7M |
| EBITDA | −$10.0MT (source: Derived: trailing 12 months at year end) | −$18.5M | −$6.7M | −$5.8M |
| EBIT | −$10.0MT (source: Derived: trailing 12 months at year end) | −$18.5M | −$6.7M | −$6.1M |
| Interest expense | $737.3KT (source: Derived: trailing 12 months at year end) | n/a | n/a | $81.9K |
| Pretax income | −$10.7MT (source: Derived: trailing 12 months at year end) | −$16.6M | −$8.9M | −$6.2M |
| Tax | $0T (source: Derived: trailing 12 months at year end) | $0 | $0 | $0 |
| NPAT | −$10.7MM (source: ASX (Markit)) | −$16.6M | −$7.7M | −$6.2M |
| Net interest income | −$553.5KT (source: Derived: trailing 12 months at year end) | $344.2K | $24.5K | −$837 |
| EPS basic | −$0.018 | −$0.033 | −$0.020 | −$0.019 |
| EPS diluted | −$0.018 | −$0.033 | −$0.020 | −$0.019 |
| Shares | n/a | 500.7M | 452.6M | 353.4M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Appendix 4E and 2026 Annual ReportAnnual Results25 Aug 2026via asx_announcements
- Appendix 4C & Quarterly UpdateQuarterly Report31 Jul 2026via asx_announcements
- Appendix 4C & Quarterly UpdateQuarterly Report30 Apr 2026via asx_announcements
- Appendix 4D - Half-year Financial Report - 31 December 2025Half Year Results25 Feb 2026via asx_announcements
- Appendix 4C & Quarterly UpdateQuarterly Report30 Jan 2026via asx_announcements
- Appendix 4C & Quarterly UpdateQuarterly Report29 Oct 2025via asx_announcements
- Appendix 4E and 2025 Annual ReportAnnual Results26 Aug 2025via asx_announcements
- Appendix 4C & Quarterly UpdateQuarterly Report30 Jul 2025via asx_announcements
- Appendix 4C & Quarterly UpdateQuarterly Report28 Apr 2025via asx_announcements
- Appendix 4D - Half-year Financial Report - 31 December 2024Half Year Results17 Feb 2025via asx_announcements
Showing 10 of 82 reports